Another recent Journal Watch article about TPA – relaying the manufacturer-sponsored message that TPA can, in fact, be given to the patients who were excluded from ECASS III because of diabetes or prior stroke.
Papers like this are fabulous. I am 100% in agreement with the physiologic premise that timely reperfusion of the ischemic penumbra is beneficial in acute stroke. I am less enthusiastic about using systemic thrombolysis, because it’s akin to smashing a teacup with a sledgehammer. But, until PCI-like therapy is available/safe for the brain, it’s all we have.
I am really tired of endless papers from the TPA literature with authors falling all over themselves to present fundamentally flawed data as definitive evidence. In this paper, the authors take the non-randomized TPA population from the SITS-ISTR – and compare it to the non-randomized, non-thrombolyzed population from the VISTA registry. Why is this a problem? Because even though the relative differences are large, the absolute differences are small – and we’ve already see that what makes the largest absolute difference is stroke after-care, and that all stroke centers are not created equal. The authors acknowledge this, but then justify their results by stating that their numbers are similar to prior, retrospective, non-randomized comparisons performed on subsets of registry data. It’s a self-fulfilling prophecy.
They conclude with “Hence, we find no justification to exclude patients from receiving alteplase for acute ischemic stroke if they have a [prior stroke] and also have [diabetes mellitus]” – which is true, unless it bothers you that the mRS 6 (dead) group nearly doubles when TPA is given to the stroke/diabetes groups. Imagine what the reaction to ECASS III would be if TPA wasn’t 52% good outcome vs 6.7% death – and was one of these 29% good outcome vs. 23% death, or 25% good outcome vs. 28% death comparisons from the registry data (totally different baseline severity vs. ECASS III, just throwing the numbers out there for hyperbole).
…and, the obligatory:
Another drug company study … I am getting nauseated with all these studies trying to push something which at its best can make a difference in small group of people when cared for in perfect environment … can someone please stop these people i am fed up of TPA studies .. I am sure next study will be that it can be used in acute bleeding … bah